showed that lenalidomide bypasses the requirement of CD28 for tumor-infiltrating CD8+ T-cell activation and antitumor activity of PD-1 blockade, which suggests that lenalidomide combination is beneficial to overcome PD-1 resistant tumors infiltrated with CD28- exhausted T cells (206). Here, CD8A is linked to neoplasm.